Ozempic-maker Novo Nordisk slims down to 'Novo' / Photo: © AFP
CMSD
-0.0800
The Fort Worth Press - Ozempic-maker Novo Nordisk slims down to 'Novo'
USD
-
AED 3.672497
AFN 65.000119
ALL 79.481271
AMD 362.62989
ANG 1.790365
AOA 917.000249
ARS 1507.914969
AUD 1.403184
AWG 1.8
AZN 1.706631
BAM 1.694272
BBD 2.013497
BDT 123.063329
BGN 1.683441
BHD 0.376919
BIF 2988.746719
BMD 1
BND 1.270607
BOB 12.0517
BRL 5.140902
BSD 0.999688
BTN 95.472403
BWP 13.520912
BYN 3.041252
BYR 19600
BZD 2.010638
CAD 1.390455
CDF 2309.999801
CHF 0.817665
CLF 0.024184
CLP 954.929826
CNY 6.710503
CNH 6.713885
COP 3116.06
CRC 450.292803
CUC 1
CUP 26.5
CVE 95.520462
CZK 21.068498
DJF 178.029384
DKK 6.48073
DOP 59.037042
DZD 133.622921
EGP 51.970796
ERN 15
ETB 163.296978
EUR 0.86698
FJD 2.211016
FKP 0.74113
GBP 0.74215
GEL 2.601654
GGP 0.74113
GHS 11.481687
GIP 0.74113
GMD 73.999829
GNF 8789.514264
GTQ 7.634633
GYD 209.154856
HKD 7.843785
HNL 26.832184
HRK 6.530897
HTG 130.665107
HUF 318.2825
IDR 17686
ILS 3.051955
IMP 0.74113
INR 95.91105
IQD 1309.637766
IRR 1374574.999943
ISK 121.329739
JEP 0.74113
JMD 157.767074
JOD 0.709005
JPY 154.972495
KES 129.729891
KGS 87.449497
KHR 4053.451151
KMF 425.999983
KPW 900.000318
KRW 1362.979762
KWD 0.308661
KYD 0.833102
KZT 447.53803
LAK 22366.506116
LBP 89917.871151
LKR 329.004817
LRD 174.450889
LSL 16.240947
LTL 2.95274
LVL 0.60489
LYD 6.343775
MAD 9.477633
MDL 17.405315
MGA 4313.212516
MKD 53.297931
MMK 2099.455368
MNT 3599.533296
MOP 8.076908
MRU 40.148654
MUR 47.090132
MVR 15.410205
MWK 1733.514675
MXN 17.180299
MYR 4.073005
MZN 63.900892
NAD 16.240947
NGN 1325.360163
NIO 36.791905
NOK 9.345825
NPR 152.756506
NZD 1.733925
OMR 0.384498
PAB 0.999688
PEN 3.360029
PGK 4.448429
PHP 62.852016
PKR 277.147597
PLN 3.76584
PYG 6012.855608
QAR 3.654146
RON 4.560298
RSD 101.74103
RUB 84.17755
RWF 1475.103087
SAR 3.752075
SBD 8.019499
SCR 13.749214
SDG 601.499256
SEK 9.776025
SGD 1.27254
SHP 0.740713
SLE 24.650165
SLL 20969.491881
SOS 571.312242
SRD 37.767022
STD 20697.981008
STN 21.224249
SVC 8.747704
SYP 13002.000254
SZL 16.228906
THB 33.308994
TJS 9.232349
TMT 3.5
TND 2.925864
TOP 2.40776
TRY 48.639776
TTD 6.788177
TWD 31.896017
TZS 2645.62802
UAH 44.623601
UGX 3919.054714
UYU 40.264561
UZS 11766.642267
VES 841.183989
VND 25954.5
VUV 118.087796
WST 2.731498
XAF 568.701579
XAG 0.015922
XAU 0.000234
XCD 2.70255
XCG 1.80177
XDR 0.707052
XOF 568.701579
XPF 103.312211
YER 236.524998
ZAR 16.33076
ZMK 9001.197348
ZMW 19.319796
ZWL 321.999592
SSP 5646.229811
MXV 1.948135
- China warns against space 'battlefield' after US says weapons deployed
- As Ballon d'Or vote nears, stars campaign for the award
- Denmark says Russian frigate fired flares at helicopter
- Markets on edge as US Fed meets to tackle high inflation
- EU to propose curbing social media, online games for under 15s
- International Trading Institute Expands Professional Trader Development Beyond the Master’s in Trading
- FX Junction Reaches 40,600 Members and 26 Million Trades
- Nairobi to host 2029 world athletics championships in African first
- Prominent Greek neo-Nazi exits prison, vows return to politics
- Ukraine winemakers defy war to make a splash at home
Ozempic-maker Novo Nordisk slims down to 'Novo'
Danish pharmaceuticals giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Monday a name change to just Novo, hoping it will be more "memorable and relevant" for clients.
The rebrand comes ahead of a strategic presentation on September 21, when executives are to lay out their plan for "a faster, more competitive and increasingly consumer-driven market".
The company is battling fierce competition in the anti-obesity sector, where its hugely successful Ozempic and Wegovy treatments have spurred rivals to catch up.
It released a new tablet form of Wegovy in the United States in January, and the pill was recently approved for use in Europe.
It will keep the full Novo Nordisk as its legal corporate name, using Novo and an updated version of its bull logo for its packaging.
Chief executive Mike Doustdar told Denmark's TV2 television the rebrand was part of an effort to "reinvent the company".
"People who use insulin are only considered as patients," he said.
"But over the past four or five years, we've seen the emergence of a bigger and bigger group that tells us, 'I'm not a patient, I'm not sick. I just want to lose weight'."
L.Holland--TFWP
